At what dose does Lisdexamfetamine produce psychosis?

Effects like psychosis are typically reported at common doses and above. A common oral dose of Lisdexamfetamine is 30–60 mg.

What other substances cause psychosis?

Other substances documented to produce psychosis include 1P-ETH-LAD, Methamphetamine, 3,4-CTMP, 1P-LSD, Myristicin, and 35 more.

Psychosis from Lisdexamfetamine — Detailed Guide

Q: Does Lisdexamfetamine cause psychosis?

Yes. Psychosis is a documented cognitive effect of Lisdexamfetamine. Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — characterized by firmly held false beliefs (delusions), perception of things that are not there (hallucinations), disorganized thought and speech, and a loss of the ability to distinguish internal mental events from external reality.

Psychosis from Lisdexamfetamine

cognitiveStimulants

Psychosis + Lisdexamfetamine

Effect category

cognitive

Substance class

Stimulants

Chemical class

Amphetamine, Substituted amphetamines

Routes of administration

oral

Other effects from Lisdexamfetamine

Other substances causing this effect

Psychosis + Lisdexamfetamine

Effect category

cognitive

Substance class

Stimulants

Chemical class

Amphetamine, Substituted amphetamines

Routes of administration

oral

Other Lisdexamfetamine effects

Substances causing psychosis

Lisdexamfetamine is known to produce psychosis, a cognitive effect. Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — characterized by firmly held false beliefs (delusions), perception of things that are not there (hallucinations), disorganized thought and speech, and a loss of the ability to distinguish internal mental events from external reality.

About Psychosis

Psychosis represents one of the most severe adverse cognitive outcomes associated with psychoactive substance use. It is not a single symptom but a syndrome — a constellation of related disruptions to perception, belief, and thought that collectively produce a state in which the person has lost meaningful contact with shared reality. The defining features include delusions (fixed false beliefs maintained with absolute conviction),hallucinations (perceiving things that are not present, across any sensory modality),thought disorder (disorganized, incoherent, or tangential thinking and speech), andloss of insight (the inability to recognize that one's perceptions and beliefs are abnormal).

What distinguishes psychosis from the altered perceptions produced by a "normal" psychedelic or dissociative experience is fundamentally about insight. A person having a psychedelic trip may see geometric patterns overlay their visual field, but they know they have taken a substance and that the patterns are drug-induced. A person experiencing psychosis may see the same patterns but believe they represent coded messages from a government surveillance network — and no amount of rational argument can shake this conviction. The loss of the ability to reality-test one's own perceptions is the critical threshold that separates an altered state from a psychotic one.

Substance-induced psychosis can arise through several pathways. Acute intoxication psychosis can occur with high doses of psychedelics, stimulants, cannabis, and deliriants — the sheer intensity of the altered state overwhelms the person's capacity to maintain orientation.Stimulant psychosis is particularly well-documented: extended use of amphetamines, methamphetamine, or cocaine, especially combined with sleep deprivation, can produce a paranoid psychotic state that closely resembles acute schizophrenia, complete with persecutory delusions, auditory hallucinations, and disorganized behavior.Cannabis-induced psychosis can occur in predisposed individuals, sometimes after a single heavy exposure.Withdrawal psychosis can accompany withdrawal from alcohol and benzodiazepines.

The relationship between substance use and psychosis is bidirectional and complex. Substances can trigger psychotic episodes in individuals with latent vulnerability (genetic predisposition to schizophrenia-spectrum disorders), can worsen existing psychotic conditions, and can produce transient psychotic states in individuals with no underlying vulnerability. Cannabis use during adolescence has been identified as a significant risk factor for the later development of psychotic disorders, with a dose-response relationship. However, most people who use these substances never experience psychosis, and the interaction between substance exposure and individual vulnerability is not well enough understood to predict individual risk.

Harm reduction note: Psychosis is a psychiatric emergency. If someone has lost contact with reality — believing things that are clearly not true, acting on hallucinated perceptions, unable to recognize that they are intoxicated — they need professional help. Do not attempt to argue them out of delusions, as this typically escalates agitation. Ensure physical safety, speak calmly and simply, and call for medical assistance. Individuals with a personal or family history of psychotic disorders should exercise extreme caution with all psychoactive substances, particularly cannabis, psychedelics, and stimulants.

How Lisdexamfetamine Produces This Effect

Lisdexamfetamine was developed with the goal of providing a long duration of effect that remains consistent throughout the day as well as reduced potential for abuse. The attachment of the amino acid lysine slows down the relative amount of dextroamphetamine that is released into the bloodstream. Because no free dextroamphetamine is present in lisdexamfetamine capsules, dextroamphetamine does not become available through mechanical manipulation, such as crushing or simple extraction. There is, therefore, no way to speed up absorption via alternate routes of administration, such as via insufflation, vaporization, or injection, making the drug theoretically less abusable.

Pharmacokinetics

As a prodrug, lisdexamfetamine is inactive in the form administered. Once ingested, it is enzymatically cleaved into two parts: L-lysine, a naturally occurring essential amino acid, and d-amphetamine, a central nervous system stimulant. Thus lisdexamfetamine functions as an extended release version of dexamphetamine. Because d-amphetamine needs to be liberated from lysine via contact with red blood cells, effects are independent of route of administration. Conversion of lisdexamfetamine into active d-amphetamine is enzymatically rate-limited, slowing down the time to achieve peak concentrations and decreasing its magnitude and dampening consequent striatal dopamine release, which is thought to be responsible for the euphoric and compulsive redosing effects of stimulants.

Pharmacodymanics

Amphetamine is a full agonist of the trace amine-associated receptor 1 (TAAR1), which is a key regulator of common and trace brain monoamines such as dopamine, serotonin and noradrenaline. The agonism of this set of receptors results in the release of increased concentrations of dopamine, serotonin and noradrenaline in the synaptic cleft. This leads to cognitive and physical stimulation within the user.

d-amphetamine's affinity for the TAAR1 receptor is twice that of l-amphetamine. As a result, d-amphetamine produces three to four times as much central nervous system (CNS) stimulation as l-amphetamine. l-amphetamine, on the other hand, has stronger cardiovascular and peripheral effects.

Conversion rate

29.7% of the weight of lisdexamfetamine dimesylate (the usual prescribed form) is dexamphetamine: 30 mg lisdexamfetamine dimesylate is equivalent to 8.9 mg of dexamfetamine.

The subjective experience will differ due to the slower, more steady release of active substance in the prodrug. An equivalent dose of dexamphetamine will have a higher peak plasma concentration and shorter duration.

While the subjective effects are essential identical to that of dextroamphetamine, and thus amphetamine, lisdexamfetamine is significantly longer in duration and more consistent in intensity due to its slow release. Although this drug is rate-limited in its metabolism, sufficiently high doses are comparable to its instant release counterparts once the peak has been reached.

Peripheral effects (such as increased heart rate and higher body temperature) are reported to be less prominent than formulations that partly contain l-amphetamine, such as Adderall or the racemic amphetamine sulphate sold illicitly.

In rodents and primates, sufficiently high doses of amphetamine cause dopaminergic neurotoxicity, or damage to dopamine neurons, which is characterized by reduced transporter and receptor function. There is no evidence that amphetamine is directly neurotoxic in humans. However, large doses of amphetamine may cause indirect neurotoxicity as a result of increased oxidative stress from reactive oxygen species and autoxidation of dopamine.

It is strongly recommended that one use harm reduction practices when using this drug.

Addiction is a serious risk with heavy recreational amphetamine use, but is unlikely to arise from typical long-term medical use at therapeutic doses. Lisdexamfetamine has been posited to have less potential for abuse and addiction than other pharmaceutical amphetamines due to the slower onset and the self-limiting metabolism, which puts a cap on the maximum peak plasma concentration and consequent dopamine release. Caution is nonetheless advised, as with other drugs in the amphetamine class.

Tolerance develops rapidly in amphetamine abuse (i.e. a recreational amphetamine overdose), so periods of extended use often require increasingly larger doses of the drug in order to achieve the same effect. Repeated use of lisdexamfetamine results in a gradual tolerance proportional to the dosage taken. Patients prescribed this drug often must increase their dosage after a time to maintain its efficacy.

Psychosis

Using amphetamines in very high doses can result in stimulant psychosis which may include symptoms such as paranoia, delusions, and hallucinations, including the infamous Shadow people. A Cochrane Collaboration review on treatment for amphetamine, dextroamphetamine, and methamphetamine psychosis states that about 5–15% of users fail to recover completely. According to the same review, there is at least one trial that shows antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis. Psychosis very rarely arises from therapeutic use. The combination of prolonged use of high doses combined with sleep deprivation significantly increases the risk of stimulant psychosis

Lisdexamphetamine is approved for medical use with a doctor's prescription, but in most countries it is illegal to sell or possess without a prescription. It requires a special certificate while traveling within the Schengen Area, which covers most of Europe, but not the United Kingdom.

Australia: It is a Schedule 8 drug.
Canada: Lisdexamfetamine, as well as other amphetamines, is a Schedule I drug.
Germany: Lisdexamfetamine is controlled under Anlage III BtMG (Narcotics Act, Schedule III) as of July 17, 2013. It can only be prescribed on a narcotic prescription form.
Norway: Lisdexamfetamine is a Class A drug under particularly strict control.
Sweden: Lisdexamfetamine is a Class II narcotic, with strict requirements for prescription. It has been placed under "utökad övervakning" (extended surveillance).
Switzerland: Lisdexamphetamine is a controlled substance as of October 1, 2014 specifically named under Verzeichnis A. Medicinal use is permitted.
United Kingdom: Lisdexamfetamine is a Schedule II, Class B controlled drug.
United States: Lisdexamfetamine is a Schedule II controlled drug.
Responsible use
Stimulants
Amphetamine
Methylphenidate
Lisdexamfetamine (Wikipedia)
Lisdexamfetamine (Isomer Design)
Lisdexamfetamine (DrugBank)
Lisdexamfetamine (Drugs.com)
Dextroamphetamine and Amphetamine (MedicinePlus)
Galli, A., Poulsen, N.W., Sulzer, D., & Sonders, M.S. (2005). Mechanisms of neurotransmitter release by amphetamines: a review. Progress in Neurobiology, 75 6, 406-33. https://doi.org/10.1016/j.pneurobio.2005.04.003
Berman, S. M., Kuczenski, R., McCracken, J. T., & London, E. D. (2009). Potential adverse effects of amphetamine treatment on brain and behavior: a review. Molecular Psychiatry, 14(2), 123. https://doi.org/10.1038/mp.2008.90.

Lisdexamfetamine can be administered via oral. The route of administration can influence both the onset and intensity of psychosis.

Psychosis from Lisdexamfetamine

Psychosis + Lisdexamfetamine

Psychosis + Lisdexamfetamine

About Psychosis

How Lisdexamfetamine Produces This Effect

Dosage Context

oral

Other Substances That Cause Psychosis (40)

Cannabinoid

Deliriant

Depressant

Dissociatives

Dissociatives, Psychedelic

Entactogen, Stimulants

Essential nutrient, Neurotransmitter cofactor

Neurotransmitter

Psychedelic

Stimulants

See Also

Frequently Asked Questions

Psychosis from Lisdexamfetamine

Psychosis + Lisdexamfetamine

Psychosis + Lisdexamfetamine

About Psychosis

How Lisdexamfetamine Produces This Effect

Dosage Context

oral

Other Effects from Lisdexamfetamine (54)

Other Substances That Cause Psychosis (40)

Cannabinoid

Deliriant

Depressant

Dissociatives

Dissociatives, Psychedelic

Entactogen, Stimulants

Essential nutrient, Neurotransmitter cofactor

Neurotransmitter

Psychedelic

Stimulants

See Also

Frequently Asked Questions